Welcome to FreedomWorks Foundation’s fifth regulatory review of 2019! Our Regulatory Action Center proudly updates you with our favorite tidbits from the swamp. We want to smash barriers between bureaucracy and the American people by delivering regulatory news straight to FreedomWorks activists. Check back in two weeks for the next edition.

Welcome to FreedomWorks Foundation’s second regulatory review of 2019! Our Regulatory Action Center proudly updates you with our favorite tidbits from the swamp. We want to smash barriers between bureaucracy and the American people by delivering regulatory news straight to FreedomWorks activists. Check back in two weeks for the next edition.

Schedule:

In his first address to Congress last month, President Trump criticized the Food and Drug Administration’s “slow and burdensome” drug approval process for preventing “too many advances…from reaching those in need.” Indeed, the FDA has repeatedly proven to be a bureaucratic quagmire that slows the development of effective, affordable medication and helps to inflate the price of some drugs to absurd levels.